| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 17, 2005
Accepted on June 9, 2005
From the Departments of Cell and Molecular Physiology (D.C., S.M.M., H.Z., J.E.F.) and Biochemistry (S.W.S., D.C.L.), University of North Carolina, Chapel Hill.
* To whom correspondence should be addressed. E-mail: jefaber{at}med.unc.edu.
Objective--Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a potent mitogen for smooth muscle cells and has been implicated in atherosclerosis, tissue regeneration after ischemia, vascular development, and tumor angiogenesis. We examined the hypothesis that HB-EGF participates in angiogenesis and collateral growth in ischemia.
Methods and Results--During 3 weeks after femoral artery ligation, no attenuation occurred in recovery of hindlimb perfusion or distal saphenous artery flow in HB-EGF-null (HB-EGF-/-) versus wild-type mice. Lumen diameters of remodeled collaterals in gracilis muscle were similar by morphometry (87±8 versus 94±6 µm) and angiography, although medial thickening was reduced. Gastrocnemius muscle underwent comparable angiogenesis (41% and 33% increase in capillary-to-muscle fiber ratio). Renal renin mRNA, arterial pressure, and heart rate during anesthesia or conscious unrestrained conditions were similar between groups. These latter findings validate comparisons of perfusion data and also suggest that differences in arterial pressure and/or renin-angiotensin activity are not masking an otherwise inhibitory effect of HB-EGF absence. Four days after ligation, EGF receptor phosphorylation increased in muscle by 104% in wild-type but by only 30% in HB-EGF-/- mice. This argues against compensation by other EGF receptor ligands.
Conclusion--Our results suggest that HB-EGF is not required for arteriogenesis or angiogenesis in hindlimb ischemia.
This article has been cited by other articles:
![]() |
S. Belmadani, K. Matrougui, C. Kolz, Y. F. Pung, D. Palen, D. J. Prockop, and W. M. Chilian Amplification of Coronary Arteriogenic Capacity of Multipotent Stromal Cells by Epidermal Growth Factor Arterioscler Thromb Vasc Biol, June 1, 2009; 29(6): 802 - 808. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Distasi, J. Case, M. A. Ziegler, M. C. Dinauer, M. C. Yoder, L. S. Haneline, M. C. Dalsing, S. J. Miller, C. A. Labarrere, M. P. Murphy, et al. Suppressed hindlimb perfusion in Rac2-/- and Nox2-/- mice does not result from impaired collateral growth Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H877 - H886. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhang, S. W. Sunnarborg, K. K. McNaughton, T. G. Johns, D. C. Lee, and J. E. Faber Heparin-Binding Epidermal Growth Factor-Like Growth Factor Signaling in Flow-Induced Arterial Remodeling Circ. Res., May 23, 2008; 102(10): 1275 - 1285. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chalothorn, J. A. Clayton, H. Zhang, D. Pomp, and J. E. Faber Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains Physiol Genomics, July 18, 2007; 30(2): 179 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ryzhov, J. L. McCaleb, A. E. Goldstein, I. Biaggioni, and I. Feoktistov Role of Adenosine Receptors in the Regulation of Angiogenic Factors and Neovascularization in Hypoxia J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 565 - 572. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |